Metabolon’s Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize…
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology
CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
GLOBAL MANCOZEB SUMMIT: ADDRESSING ITS CRUCIAL ROLE IN CROP PROTECTION AHEAD OF EU COURT HEARING
LONDON, June 16, 2025 /PRNewswire/ --Â UPL Corporation Ltd. (UPL Corp) - part…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test
PORTOLA VALLEY, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme…
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology. FREMONT,…